Recent reports of adverse reactions have prompted health authorities in the UK to investigate potential links between GLP-1 medications and acute pancreatitis. The Medicines and Healthcare products Regulatory Agency (MHRA) has recorded nearly 400 cases of acute pancreatitis related to drugs such as Mounjaro and Ozempic, with over a quarter reported in 2025 alone. Symptoms of acute pancreatitis are severe abdominal pain and possible hospitalization. The MHRA aims to identify any genetic factors contributing to the increase in cases and encourages reporting of suspected cases to enhance patient safety.
The Medicines and Healthcare products Regulatory Agency is investigating reports of pancreatitis linked to GLP-1 medications, prompting concerns about the safety of these weight loss and diabetes treatments.
Over 400 cases of acute pancreatitis have been reported among patients taking GLP-1 medications like Mounjaro and Ozempic, raising significant safety concerns and prompting further studies.
Collection
[
|
...
]